Connection
Lynn Heasley to Carcinoma, Small Cell
This is a "connection" page, showing publications Lynn Heasley has written about Carcinoma, Small Cell.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.322 |
|
|
|
-
Hinz TK, Kalkur R, Rabinovitch J, Hinkle W, Heasley LE. TP53 Null Mutations Identify Lung Cancer Cell Lines with Highest Sensitivity to the Nontaxane Microtubule Inhibitor Eribulin. Mol Pharmacol. 2021 08; 100(2):144-154.
Score: 0.738
-
Bunn PA, Soriano A, Johnson G, Heasley L. New therapeutic strategies for lung cancer: biology and molecular biology come of age. Chest. 2000 Apr; 117(4 Suppl 1):163S-168S.
Score: 0.171
-
Beekman A, Helfrich B, Bunn PA, Heasley LE. Expression of catalytically inactive phospholipase Cbeta disrupts phospholipase Cbeta and mitogen-activated protein kinase signaling and inhibits small cell lung cancer growth. Cancer Res. 1998 Mar 01; 58(5):910-3.
Score: 0.148
-
Butterfield L, Storey B, Maas L, Heasley LE. c-Jun NH2-terminal kinase regulation of the apoptotic response of small cell lung cancer cells to ultraviolet radiation. J Biol Chem. 1997 Apr 11; 272(15):10110-6.
Score: 0.139
-
Heasley LE, Zamarripa J, Storey B, Helfrich B, Mitchell FM, Bunn PA, Johnson GL. Discordant signal transduction and growth inhibition of small cell lung carcinomas induced by expression of GTPase-deficient G alpha 16. J Biol Chem. 1996 Jan 05; 271(1):349-54.
Score: 0.127